FIELD: pharmaceutics.SUBSTANCE: invention relates to levocarrimycin and use thereof for development of medicines for infectious diseases. Disclosed levocarrimycin is a mixture of isovalerylspiramycin III, II and I as main component and comprises one of following components: isobutyrylspiramycin III and II, butyrylspiramycin III and II, propionylspiramycin III and II, as well as acetylspiramycin III and II, wherein content of isovalerylspiramycin III is not less than 30 wt%, total content of isovalerylspiramycin III, II and I is not less than 60 wt%, and content of acylspiramycin from 80 to 98 wt% and said levocarrimycin also contains spiramycin III and other components, among which content spiramycin III does not exceed 1.0%, and total content of other components ranges from 2.0 to 19 wt%, the spiramycin III is characterised by peaks at 2θ = 8.0°, 10.0°, 11.2°, 11.7°, 16.4°, 19.1°, 19.6°, 20.0°, 21.4°, 22.9°, 23.6° and 29.4°, spiramycin II is characterised by peaks at 2θ = 10.0°, 11.6°, 16.4°, 17.3°, 19.1°, 21.2°, 22.1°, 22.7°, 26.4°, 26.9°, 27.5° and 31.5° and spiramycin I is characterised by peaks at 2θ = 7.6°, 8.0°, 10.0°, 11.4°, 16.4°, 17.0°, 17.5°, 17.9°, 19.5°, 22.7°, 23.7° and 24.4° in X-ray powder diffraction, measured using radiation of Cu-Kα； said levocarrimycin is obtained by culturing cloned strain WSJ-195 bacteria which produce spiramycin, fermentation, extraction with subsequent chromatography and collecting desired peak； Ior, II levoisovalerylspiramycin recrystallisation III； mixing obtained crystalline levoisovalerylspiramycin I, II or III with levocarrimycin obtained by chromatography.EFFECT: novel antibiotic formulation possessing higher solubility and efficiency.18 cl, 46 ex, 6 tbl, 8 dwgИзобретение относится к левокарримицину и его использованию для создания лекарств против инфекционных заболеваний. Предложенный левокарримицин представляет собой смесь изовалерилспирамицина III, II и I в качестве основного компонента и содержит один из следующих
